Your Directors have pleasure in presenting their 39^th
Annual Report together with the Audited Accounts of
the Company for the Year ended March 31, 2025.

1) FINANCIAL RESULT (Rs. In Lacs)

2) OPERATIONAL REVIEW:

The Financial year passed by that is FY 2024-25 was a
challenging year for the entire consumption oriented
business including Pharmaceuticals. Further, the
geopolitical scenario which was getting worsen day by
day put more pressure on consumption oriented
industries.

In spite of all these, the total revenue of your Company
during FY 2024-25 stood at Rs. 682.56 Lacs compared
to Rs. 730.46 Lacs during FY 2023-24.

The Revenue from operations stood at Rs. 652.77 Lacs
(Net of GST) and the Income by way of Interest and
dividend received was Rs. 29.79 Lacs.

During the year under review;

1) Profit before tax stood at Rs. 61.94 Lacs compared to
65.03 Lacs in the corresponding previous year.

2) Net profit after providing for taxes and adjustment of
differed tax credit stood at 49.66 Lacs. (Previous year
Rs. 48.67 Lacs)

3) Other Comprehensive Income stood at Rs.2.89 Lacs.

4) Carried to Balance Sheet: Rs. 52.55 Lacs.

3) DIVIDEND:

The Board regrets its inability to recommend any
dividend to plough back the surplus available and to
strengthen the financial resources of the Company.

4) SHARE CAPITAL:

The paid up equity capital as on March 31, 2025, was
Rs 251.91 Lacs. During the year under review your
Company has not issued any shares public, rights,
preferential including Sweat equity, ESOP and/or
convertible debentures.

5) CHANGE IN THE NATURE OF BUSINESS:

During the year under review, there is no change in the
nature of business pursuant to section 134 of the
Companies Act,2013.

6) FINANCE & MATERIAL CHANGES AFFECTING
FINANCIAL POSITION OF THE COMPANY:

The Company continues to focus on judicious
management of its working capital, receivables,
inventories and other working capital parameters.
They are kept under strict check through continuous
monitoring. No material changes have occurred and
commitments made, affecting the financial position of
the Company.

7) PUBLIC DEPOSITS:

Your Company has not accepted any deposits within the
meaning of Section 73 of the Companies Act, 2013 and
the Companies (Acceptance of Deposits) Rules, 2014.

8) PARTICULARS OF LOANS, GUARANTEES OR
INVESTMENTS:

The Company has not made any investments, given any
loans or guarantees covered under the provisions of
section 186 of the Companies Act, 2013.

9) INTERNAL CONTROL SYSTEMS AND THEIR
ADEQUACY

The Company has an Internal Control System,
commensurate with the size, scale and complexity of its
operations. The scope and authority of the Internal
Audit function is defined. To maintain its objectivity
and independence, the Internal Audit function reports
to the Chairman of the Audit Committee of the Board.

The Board has adopted the procedures for ensuring the
orderly and efficient conduct of its business, including
adherence to the Company's policies, the safeguarding
of its assets, the prevention and detection of frauds and
errors, the accuracy and completeness of the accounting
record and the timely preparation of reliable financial
disclosures.

The Internal Audit Department monitors and evaluates
the efficacy and adequacy of internal control system in
the Company, its compliance with operating systems,
accounting procedures and policies at all locations of the
Company. The Audit Committee reviews the adequacy
and effectiveness of the internal control system and
suggests improvement to strengthen the system. It also
reviews the quarterly internal Audit Reports submitted
by the Internal Auditors.

10) CORPORATE SOCIAL RESPONSIBILITY
INITIATIVES:

Not applicable to the Company, since the Company is
outside the threshold limit under the Companies Act,
2013 as amended from time to time.

11) DIRECTORS:

Retirement by rotation and subsequent
reappointment.

Dr. Mani L. S. (DIN - 00825886), Director of the
Company is liable to retire by rotation at the ensuing
Annual General Meeting (“AGM”) pursuant to the
provisions of Section 152 of the Companies Act, 2013

read with the Companies (Appointment and
Qualification of Directors) Rules, 2014 and being eligible
offers himself for re-appointment. Appropriate
resolution for his reappointment is being placed for the
approval by the Members of the Company at the ensuing
AGM.

A brief profile of Directors seeking appointment/ re¬
appointment at the AGM and other related information
is detailed in the Notice convening the 39th AGM of your
Company.

The Board considered the said re-appointment is in the
interest of the Company and hence recommend the
same to the Members for approval. (Appointment/ Re¬
appointment of Non- Independent Directors.)

Appointment of Mr. Swapnil Jayeshbhai Madiyar as
a Non-Executive Non-Independent Director

During the year under review, Mr. Swapnil Jayeshbhai
Madiyar (DIN: 08520796) was appointed as an
Additional Director of the Company in the capacity of a
Non-Executive, Non-Independent Director with effect
from 16th May 2025, pursuant to the provisions of
Section 161(1) of the Companies Act, 2013 and the
Articles of Association of the Company.

In terms of the said provisions, he holds office up to the
date of the ensuing Annual General Meeting, The
Company has received a notice in writing under Section
160(1) of the Companies Act, 2013 from a member
proposing his candidature for appointment as a
Director.

The appointment of Mr. Swapnil Jayeshbhai Madiyar has
been recommended by the Nomination and
Remuneration Committee and approved by the Board of
Directors, and accordingly, the requirement of deposit
under the proviso to Section 160(1) of the Act shall not
apply.

The Board has proposed his appointment as a Director
(liable to retire by rotation) at the forthcoming Annual
General Meeting, for the approval of the Members.

12) EVALUATION OF BOARDS PERFORMANCE:

During the year, the Board has adopted a formal
mechanism for evaluating the performance and as well
as that of its Committees and Individual Directors
including the Managing Director if any and the Whole
Time Director of the Board. The exercise was carried out
by the Independent Directors of the Company through a
Structured evaluation process covering several aspects
of functioning of the Board i.e. attendance, contribution
at the meeting and otherwise, independent judgment,

safeguarding interest of the minority stakeholders,
composition of Board/Committees, performance of
specific duties and obligations by members of the Board,
etc.

13) NOMINATION & REMUNERATION POLICY:

Pursuant to section 178 of the Companies Act 2013, and
the rules made thereunder, from time to time and
Regulation 19 of the SEBI Regulations 2015, the Board
has constituted the Nomination & Remuneration
Committee. The Nomination & Remuneration
Committee framed a policy for selection and
appointment, reappointment, removal, appraisal of
Directors and Senior Management Personnel and their
remuneration.

14) MEETINGS OF BOARD OF DIRECTORS AND
AUDIT COMMITTEE:

During the year 5 Board Meetings and 4 Audit
Committee Meetings and 2 independent Directors
meeting were convened and held, the details of which
are given in the Corporate Governance Report. The
intervening gap between the Meetings was within the
period prescribed under the Companies Act, 2013.
Complete details are given in Corporate Governance
Report.

15) RELATED PARTY TRANSACTIONS:

All related party transactions, including
agreements/contracts, that were entered into during
the financial year were on arm's length basis and were
in the ordinary course of the business. There are no
materially significant related party transactions made
by the company with Promoters, Key Managerial
Personnel or other designated persons which may have
potential conflict with interest of the company at large.
Prior omnibus approval of the Audit Committee has
been obtained on an annual basis for transactions with
related parties which are of a foreseeable and repetitive
nature. The transactions entered into pursuant to the
omnibus approval so granted and a statement giving
details of all transactions with related parties are placed
before the Audit Committee for their review on a
periodic basis.

The policy on Related Party Transactions, as approved
by the Board of Directors, has been uploaded on the
website of the at : www.findoc-cll.in

16) SUBSIDIARY COMPANIES:

The Company does not have any subsidiary.

17) RISK MANAGEMENT

The Company in accordance with the provisions of the
Act has adopted a Risk Management Policy. The
Company has identified the risks impacting the business
and formulated policies for mitigation of risks.

The Company has constituted a business risk
management committee under the Companies Act, 2013
and Regulation 21 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015.

For the key business risks identified by the Company,
please refer to the Management Discussion and Analysis
annexed to this Report.

18) CODE OF CONDUCT:

The Board of Directors has approved a Code of Conduct
which is applicable to the Members of the Board and all
employees in the course of day to day business
operations of the Company. The Company believes in
“Zero Tolerance” against bribery, corruption and
unethical dealing/behaviors of any form and the Board
has laid down the directives to counter such acts. The
code laid down by the Board is known as “Code of
business conduct”.

The Code lays down the standard procedure of business
conduct which is expected to be followed by the
Directors and the designated employees in their
business dealings and in particular on matters relating
to integrity in the work place, in business practices and
in dealing with stakeholders. The Code gives guidance
through examples on the expected behavior from an
employee in a given situation and the reporting
structure.

All the Board Members and the Senior Management
personnel have confirmed compliance with the Code.
All Management Staff were given appropriate training in
this regard. The Code of Conduct in detail is given in our
Website.

19) VIGIL MECHANISM/WHISTLE BLOWER POLICY

The Company has a Fraud Risk and Management Policy
to deal with instances of fraud and mismanagement, if
any. The FRM Policy ensures that strict confidentiality
is maintained whilst dealing with concerns and also that
no discrimination will be meted out to any person for a
genuinely raised concern.

The Board of Directors has adopted Whistle Blower
Policy. The Whistle Blower Policy aims for conducting
the affairs in a fair and transparent manner by adopting

highest standards of professionalism, honesty, integrity
and ethical behavior. All permanent employees of the
Company are covered under the Whistle Blower Policy.

20) PREVENTION OF INSIDER TRADING:

The Company has adopted a Code of Conduct for
Prevention of Insider Trading with a view to regulate
trading in securities by the Directors and designated
employees of the Company. The Code requires pre¬
clearance for dealing in the Company's shares and
prohibits the purchase or sale of Company shares by the
Directors and the designated employees while in
possession of unpublished price sensitive information
in relation to the Company and during the period when
the Trading Window is closed. The Board is responsible
for implementation of the Code. All Board of Directors
and the designated employees have confirmed
compliance with the Code. Company has installed
Structural Digital Database software as required by SEBI
Regulation for (Prohibition of Insider Trading)
Regulations, 2015.

21) DISCLOSURE UNDER THE SEXUAL HARASSMENT
OF WOMEN AT WORKPLACE (PREVENTION,
PROHIBITION AND REDRESSAL) ACT,2013. :

The Company has in place an Anti- Sexual Harassment
Policy in line with the requirements of The Sexual
Harassment of Women at the Workplace (Prevention,
Prohibition & Redressal) Act, 2013. The detailed report
is given in the Reports on Corporate Governance.

22) STATUTORY AUDITORS:

M/s. Vora & Associates, Chartered Accountants, FRN.
111612W, the auditors of the Company, have been
appointed for a period of 5 years in the 36^th AGM to hold
office until the conclusion of 41^st AGM.

23) STATUTORY AUDITORS' QUALIFICATIONS/
RESERVATIONS/ADVERSE REMARKS/ FRAUDS
REPORTED:

There are no Auditors' Qualifications or reservations or
adverse remarks on the financial statements of the
Company. The Auditors have not reported any frauds to
the Audit Committee as prescribed under Section
143(12) of the Companies Act, 2013.

24) SECRETARIAL STANDARDS:

The Company has complied with the provisions
of secretarial standards of:

SS-1(Minutes of Board of Directors) and
SS-2(Annual General Meeting).

25) SECRETARIAL AUDIT AND AUDIT REPORT:

Pursuant to provisions of section 204 of the Companies
Act, 2013 and The Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014,
the Company has appointed M/s Sanjay Dholakia &
Associates, (CP No. 1798) a firm of Company Secretaries
in practice to undertake the Secretarial Audit of the
Company. The Secretarial Audit report for FY 2024-25
is annexed herewith.

26) INTERNAL AUDIT:

Internal Audit is conducted by Nagendra Gupta & Co..
For FY-2024-25.

27) COST AUDIT:

The provision of Cost Audit Report is not applicable to
the Company.

28) ANNUAL RETURN:

The Annual Return of the Company has been placed on
the website of the company and can accessed at the
Company's website at www.findoc-cll.in.

29) PARTICULARS OF EMPLOYEES:

There are no employees in receipt of remuneration
exceeding the limit as prescribed under the provisions
of Section 197 of the Companies Act, 2013.

30) EMPLOYEE RELATION AND HUMAN RESOURCES:

Industrial/Employee relation during the period under
review remained cordial at all levels. The Company has
a structured appraisal system based on key result areas.
The HR is effectively involved in nurturing, enhancing
and retaining talent through job satisfaction,
development and training programs etc.

31) CORPORATE GOVERNANCE AND MANAGEMENT
DISCUSSION & ANALYSIS REPORTS:

The Corporate Governance and Management Discussion
& Analysis Report, which form an integral part of this
Report, are set out as separate Annexure.

32) MANAGEMENT DISCUSSION & ANALYSIS:

Various business aspects including market conditions,
business opportunities, challenges etc. have been
discussed at length in the Management Discussion and
Analysis (MD & A), which forms part of this Annual
Report, as required under SEBI(LODR).

33) DEMATERIALISATION OF SHARES:

The Company has entered into agreements with both
National Securities Depository Limited (NSDL) and
Central Depository Services Limited (CDSL) whereby
the shareholders have an option to dematerialize their
shares with either of the Depository. As on 31st March
2025 total 73.25 % of the equity share of the company
has been dematerialized.

34) DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of Section 134 (5) of the Companies Act,
2013, the Directors would like to state that:

i) In the preparation of the annual accounts, the
applicable accounting standards have been
followed;

ii) The Directors have selected such accounting
policies and applied them consistently and made
judgments and estimates that were reasonable
and prudent so as to give a true and fair view of
the state of affairs of the Company at the end of
the financial year 31-03-2025 and of the profit or
loss of the Company for the year under review;

iii) The Directors have taken proper and sufficient
care for the maintenance of adequate accounting
records in accordance with the provisions of this
Act for safeguarding the assets of the Company
and for preventing and detecting fraud and other
irregularities;

iv) The Directors have prepared the annual
accounts, on a going concern basis;

v) The Directors had laid down internal financial
controls to be followed by the Company and that
such internal financial controls are adequate and
were operating effectively; and

vi) The Directors had devised proper system to
ensure compliance with the provisions of all
applicable laws and that such system was
adequate and operating effectively.

35) SIGNIFICANT ORDERS PASSED BY REGULATORS
OR COURTS OR TRIBUNAL:

There are no significant material orders passed by
the Regulators / Courts /Tribunals which would
impact the going concern status of the Company and
its future operations.

36) KEY MANAGERIAL PERSONNEL:

In terms of Section 203 of the Act, the following were
the KMPs of the Company as on 31^st March, 2025.

1. Mr. N. K. Menon, Whole-Time Director & CEO

2. CA Mr. Bhavik A. Shah, Independent Director

3. Mr. B. B. Dias, Independent Director

4. Dr. Mani L. S., Director & Company Secretary

5. Mr. Ganesh Chitte, CFO

37) LISTING FEES -BSE:

The equity shares of the Company are listed on BSE LTD.
The Company has paid Listing fees to BSE for the year
2025-26.

38) CONSERVATION OF ENERGY:

a) Company ensures that the manufacturing operations

are conducted in the manner whereby optimum
utilization and maximum possible savings of energy
is achieved.

b) No specific investment has been made in reduction
in energy consumption during the year under
review. Pharmaceutical formulation industry does
not consume high power.

c) As the impact of measures taken for conservation and
optimum utilization of energy are not quantitative,
its impact on cost cannot be stated accurately.

39) TECHNOLOGY ABSORPTION:

Company's products are manufactured by using in¬
house know how and no outside technology is being
used for manufacturing activities. Therefore, technology
absorption is a continuous process. The Company
constantly strives for maintenance and improvement in
quality of its products and entire development activities
are directed to achieve the aforesaid goal.

40) FOREIGN EXCHANGE EARNINGS AND OUT-GO:

During the period under review there was no foreign
exchange earnings or out flow.

41) COMPANY'S POLICY RELATING TO DIRECTORS'
APPOINTMENT, PAYMENT OF REMUNERATION
AND DISCHARGE OF THEIR DUTIES:

The Board has duly approved and adopted a policy viz.
“Policy for Remuneration of the Directors, Key
Managerial Personnel and other Employees”
recommended by the Nomination and Remuneration
Committee relating to appointment of Directors/ Key
Managerial Personnel/ other employees, payment of

remuneration to directors/ Key Managerial Personnel/
other employees, Directors qualifications, positive
attributes, Independence of Directors and other related
matters as provided under the Companies Act, 2013. All
the remunerations to the directors/ Key Managerial
Personnel/ employees are as per the Companies Policy
viz. “Policy for Remuneration of the Directors, Key
Managerial Personnel and other Employees”

Mumbai, 31^st July,2025

Registered Office:

A-101, Pratik Industrial Estate
Mulund-Goregaon Link Road
Bhandup(W), Mumbai - 400 078.

ACKNOWLEDGEMENT

Company and its Directors wish to extend their
sincerest thanks, to the Members of the Company,
Bankers, State Government, Local Bodies, Customers,
Suppliers, Executives, Staff and Work force at all levels
for their continuous cooperation and assistance.

On behalf of the Board of Directors

COLINZ LABORATORIES LIMITED

(CIN: L24200MH1986PLC041128)

Dr. Mani L. S.

DIN 00825886
Director

Mr. N K Menon
DIN 01111297
Whole Time Director & CEO